[Articles] Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study Vebreltinib showed antitumour activity in patients with MET amplification-driven advanced NSCLC who had previously received chemotherapy or were chemotherapy-naive. Further research is needed to validate these findings. The Lancet Oncology December 23, 2025 Original source
[Articles] Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial Individualised adjuvant treatment by molecular integrated risk profile is safe and effective for patients with high-intermediate risk endometrial cancer; it spared 46% of patients with a favourable profile from adjuvant treatment, and reduces both overtreatment and undertreatment. The Lancet Oncology December 23, 2025 Original source
[Perspectives] Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK Cancer vaccines represent a transformative frontier in oncology, offering the potential to elicit durable and specific immune responses against tumour-associated or tumour-specific antigens. This technology has the potential to treat established malignancy, reduce tumour relapse, and even prevent cancer formation—improving survival outcomes. Advances in neoantigen discovery, mRNA vaccine platforms, and personalised immunotherapy have substantially enhanced the feasibility and efficacy of… The Lancet Oncology December 23, 2025 Original source
[News] UK Government launches first Men's Health Strategy On Nov 19, 2025, the UK Government launched the first Men's Health Strategy for England. The policy paper noted that, over the past decade, healthy life expectancy for men has fallen by 1·5 years and that men in parts of the country with the most poverty die on average 10 years earlier than men in parts with the least poverty.… The Lancet Oncology December 23, 2025 Original source
[News] UK–US drug pricing deal to cost NHS £3 billion as NICE increases new medicines threshold The UK has agreed a deal with the USA for a 0% tariff on pharmaceuticals in return for a 25% increase to the threshold at which the National Health Service (NHS) deems medicines to be cost-effective. The Lancet Oncology December 23, 2025 Original source
[News] New South Wales expands cancer coverage for firefighters On Nov 21, 2025, a ministerial media release announced a new legislation passed through Australian Parliament, expanding presumptive workers' compensation coverage for firefighters diagnosed with cancer. The new legislation extends the current list of 12 recognised malignancies in New South Wales, Australia, to include ten new cancers, including primary site lung, pancreatic, thyroid, and skin cancers. Reproductive cancers including cervical,… The Lancet Oncology December 23, 2025 Original source
[News] Gavi hits HPV vaccine milestone early but concerns surround future funding Gavi, the Vaccine Alliance, a public–private global health partnership with the goal of increasing access to immunisation in developing countries, is celebrating after working with lower-income countries to reach a key target to vaccinate millions of girls with the human papillomavirus (HPV) vaccine for cervical cancer in mid-November, 2025—6 weeks ahead of its original 3-year target. The Lancet Oncology December 23, 2025 Original source
[News] Europe is falling behind on targets to address AMR Antimicrobial resistance (AMR) is causing more than 35 000 deaths per year across Europe. According to estimates by the European Centre for Disease Prevention and Control (ECDC), based on 2024 data submitted by all countries in the EU and European Economic Area, Europe has met only one of five targets set to tackle the issue. The Lancet Oncology December 23, 2025 Original source
[News] WHO sets new global standard for child‑friendly cancer drugs On Nov 6, 2025, WHO published six new target product profiles for child‑friendly formulations of essential cancer medicines. The profiles aim to support the development of age‑appropriate formulations and close gaps in paediatric cancer care. The Lancet Oncology December 23, 2025 Original source
[News] Study links ultra-processed food consumption with bowel polyps in women younger than 50 years New research by Andrew T Chan (Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA) and colleagues published in JAMA Oncology shows that younger women (aged ≤50 years) who eat the highest proportions of ultra-processed foods (UPFs) are at a 45% increased risk of developing bowel polyps that can later develop into colorectal cancer. UPFs are novel branded products… The Lancet Oncology December 23, 2025 Original source
[News] Carcinogenicity of atrazine, alachlor, and vinclozolin From October to November, 2025, a Working Group of 22 scientists from 12 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of atrazine, alachlor, and vinclozolin. The Lancet Oncology December 23, 2025 Original source
[Corrections] Correction to Lancet Oncol 2025; 26: e477–87 Tang L-L, Huang C-L, Lin S-J, et al. Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas. Lancet Oncol 2025; 26: e477–87—In this Policy Review, the first sentence of Recommendation 3.3 should have read, “Posteriorly delineate the anterior third of the clivus (the cortex) if uninvolved (usually for T1… The Lancet Oncology December 23, 2025 Original source
[Corrections] Correction to Lancet Oncol 2025; 26: 1227–39 Ma D, Price K, Moore E, et al. De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial. Lancet Oncol 2025; 26: 1227–39—In table 1 of this Article, the number of participants in each AJCC 8th edition N stage and AJCC 7th edition N stage at baseline have… The Lancet Oncology December 23, 2025 Original source
[Corrections] Correction to Lancet Oncol 2025; 26: 187–99 van der Lei S, Puijk RS, Dijkstra M, et al. Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial. Lancet Oncol 2025; 26: 187–99—In this Article, all data labelled as IQR in the Summary, table 1 legend, and Results should have been labelled as range; figure 2 has also been… The Lancet Oncology December 23, 2025 Original source
[Correspondence] Tumour genetics and thyroid cancer staging We read with interest the Comment by Susan C Pitt and Megan Haymart1 on our Article on genetic modification of the American Joint Committee on Cancer (AJCC) staging system in papillary thyroid cancer2 and hold the following conservative opinions. The Lancet Oncology December 23, 2025 Original source
[Correspondence] The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer – Authors' reply We thank John P Neoptolemos and colleagues for their letter. They state that the ESPAC-1 trial set the standard of care for adjuvant therapy in resectable pancreatic cancer.1 However, ESPAC-1 set the standard of care for resected pancreatic cancer, including only those patients who had no occult metastases at surgery, underwent a resection, recovered from surgery, had no early recurrence,… The Lancet Oncology December 23, 2025 Original source
[Correspondence] The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer We congratulate Quisette P Janssen and colleagues on the phase 3 PREOPANC-2 trial.1 PREOPANC-2 was the successor of the phase 3 PREOPANC-1, which showed improved overall survival following pre-operative chemoradiotherapy and surgery versus surgery for patients with anatomically resectable or borderline resectable pancreatic ductal adenocarcinoma. In light of the superiority for post-operative FOLFIRINOX versus gemcitabine and multiple rationales for pre-operative… The Lancet Oncology December 23, 2025 Original source
[Correspondence] The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer The ESPAC1 and ESPAC1-Plus trials in 2001 and 2004 respectively established surgery and six months of adjuvant chemotherapy as the standard of care for empirically resectable pancreatic cancer. This protocol was confirmed repeatedly over the last 25 years, leading to an enormous increase in the volume of patients being treated with surgery and adjuvant chemotherapy. The development of improved cancer… The Lancet Oncology December 23, 2025 Original source
[Comment] Retraction and republication—De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer In September, 2025, The Lancet Oncology published results of the phase 3 MC1675 study on de-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma.1 After publication, the corresponding author alerted us to numerical errors present in table 1 caused by a mistranscription of the number of patients in each category of nodal staging by AJCC… The Lancet Oncology December 23, 2025 Original source
[Comment] De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer HPV-associated oropharyngeal carcinoma has a distinct biology and responds favourably to primary radiation (and surgery)-based treatments. The long-term survival benefit is, however, offset by chronic detrimental impact on health-related quality of life for cancer survivors due to treatment-related toxic effects such as dysphagia and xerostomia. Consequently, many toxicity-mitigating de-escalation methods are being explored for HPV-associated oropharyngeal carcinoma.1 Minimally invasive primary… The Lancet Oncology December 23, 2025 Original source